JAAD Leads the Pack Among Dermatology Journals in Impact Factor
JAAD Achieves Top Impact Factor in Dermatology
In an impressive affirmation of its esteemed position, the Journal of the American Academy of Dermatology has marked its territory as the leading peer-reviewed journal within the field of dermatology for the sixth consecutive year. This accolade arises from the 2024 journal impact factor (JIF) rankings recently released by the prestigious Clarivate's Journal Citation Reports (JCR) Web of Science Group.
JAAD International Makes a Strong Impression
Adding to the excitement, JAAD International, one of three notable open-access companion journals of JAAD, has made its debut at a commendable No. 10. The emergence of JAAD International shows a growing trend toward accessibility and inclusivity in dermatologic research, ensuring a broad array of global voices is represented.
Understanding Journal Impact Factors
The Journal of the American Academy of Dermatology, boasting a JIF of 11.8 with a remarkable 38,702 citations, claims the number one spot among 96 dermatology-related journals categorized by JCR. On the other hand, JAAD International recorded an impressive first impact factor of 5.2 with 1,046 citations, securing a commendable position at No. 10.
The impact factor is a crucial metric, representing the number of citations a journal's articles receive relative to its total published articles. Although it serves as a rough indicator rather than a precise average, it certainly offers valuable insights into a journal's influence during the specified timeframe, which for this ranking covers 2022-2023.
Celebrating Achievement in Dermatologic Research
Dr. Dirk M. Elston, a board-certified dermatologist and Editor-in-Chief of JAAD, expressed pride in this accomplishment, stating, "Having two journals with impact factors in the Top 10 is a momentous event that highlights the exceptional quality of our journals. We owe this success to our dedicated authors, reviewers, and editors, and we reaffirm our commitment to our goal of helping dermatologists improve patient outcomes across our portfolio of JAAD journals."
Insights from the Founding Editor of JAAD International
Dr. Jonathan Kantor, board-certified dermatologist and Founding Editor of JAAD International, shared his enthusiasm regarding their debut impact factor, noting, "This is an exceptional milestone for a dermatology journal. From the inception of JAAD International in 2020, we focused on inclusivity and quality, showcasing rigorous research from the global dermatology community. We appreciate the hard work from our entire team!"
Research and Publication Opportunities
For those interested in exploring the most recent research published in these influential journals or submitting their own work for consideration, the portals at JAAD.org and JAADinternational.org stand ready for engagement. Moreover, the comprehensive JAAD journals portfolio now includes JAAD Case Reports and the newly launched JAAD Reviews in 2024.
About the American Academy of Dermatology
Founded in 1938 and headquartered in Rosemont, Illinois, the American Academy of Dermatology is the largest and most influential dermatology association globally. With a member base exceeding 21,000 physicians around the world, this organization is fervently dedicated to advancing the field of dermatology through diagnosis, treatment, and advocacy for high standards of practice.
The AAD is profoundly committed to improving patient care, recognizing the significant impact skin, hair, and nail conditions can have on health and overall well-being. For inquiries, the AAD can be reached at (888) 462-DERM (3376) or through their official site.
JAAD: The Leading Dermatology Journal
Recognized as the most cited dermatology journal globally, JAAD was recently confirmed as the top dermatology journal in the 2024 impact factor rankings from Clarivate's Journal Citation Reports. This journal's profound impact was acknowledged in 2009 when the Special Libraries Association recognized it as one of the most influential journals over the past century. The JAAD portfolio also encompasses three open-access companion titles, marking a notable commitment to broadening access to dermatologic research.
Frequently Asked Questions
What is the impact factor of JAAD for 2024?
The impact factor of JAAD for 2024 is 11.8, solidifying its position as the leading journal in dermatology.
How many journals are included in the JCR ranking for dermatology?
There are 96 dermatology-related journals ranked by the Journal Citation Reports.
When was JAAD International launched?
JAAD International was launched in 2020 and has made an impressive debut in the latest impact factor rankings.
Who is the Editor-in-Chief of JAAD?
Dr. Dirk M. Elston serves as the Editor-in-Chief of JAAD.
What is the significance of the Journal Impact Factor?
The Journal Impact Factor provides a useful approximation of a journal's citation rate, indicating its influence within the academic community.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
